Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: KUC 7483 CL
Other: High fat meal

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT02259907

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/amlodipine fixed-dose combination (FDC) tablet
Drug: Telmisartan
Drug: Amlodipine

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259803

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL 801 CL dry syrup new formulation
Drug: WAL 801 CL dry syrup conventional formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02260050

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Epinastine tablets
Drug: Epinastine syrup

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02260063

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 113823 solution
Drug: BI 113823 tablet
Other: High fat, high calorie breakfast

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63

Registration Number: NCT02259972

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Single rising doses of BI 1744 CL, solution for oral inhalation
Drug: Placebo
Drug: Tiotropium, fixed dose, solution for oral inhalation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02259959

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Persantin® commercial formulation
Drug: Persantin® new formulation

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02259998

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Medium dose of BIBT 986 CL, per i.v. infusion
Drug: High dose of BIBT 986 CL, per i.v. infusion
Drug: Placebo
Drug: Low dose of BIBT 986 CL, per i.v. infusion
Drug: Lipopolysaccharide (LPS), single i.v. bolus

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02259881

Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: KUC 7483 CL, immediate release tablet
Drug: KUC 7483 CL, particulate formulation
Drug: KUC 7483 CL, solution formulation
Device: Enterion™ capsule

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02259920

Telmisartan in Mild to Moderate Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: Placebo

First Posted Date: 2014-10-09

Last Posted Date: 2014-10-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 134

Registration Number: NCT02260089

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy